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How can we enhance 
sexual health outcomes in 
men who have sex with 
men in Lebanon?
In Lebanese men who have sex with 
men (MSM), the prevalence of HIV is 
12% and the prevalence of having at 
least one symptom of a sexually trans-
mitted infection (STI) is 34.9%.1 Low 
HIV testing rates, unprotected unpro-
tected sexual intercourse, alcohol 
and substance use contribute to this 
epidemic.2 Here we present data on the 
prevalence of STIs in a sample of MSM 
attending a sexual health clinic in order 
to identify the correlates of risk- taking 
behaviour, and of testing behaviour 
in this population. Addressing these 
questions is crucial for reducing the 
incidence of HIV/STIs and, thus, for 
enhancing sexual health outcomes in 
this high- risk population in Lebanon.
We analysed data from the medical 
records of MSM who presented for 
STI screening and treatment between 
2014 and 2018 at a sexual health centre 
(Dermatology- STI clinic) in Beirut, 
Lebanon. Ethical approval was obtained 
from the Faculty of Health & Life 
Sciences Research Ethics Committee, 
De Montfort University, Leicester, UK 
(Ref. 3082).
MSM attending the clinic completed 
a short survey and the data were added 
to their medical records. The sample 
consisted of 1364 participants for 
whom data were complete and thus 
were included in the analysis. The 
most frequent STIs were genital warts 
(41.13%), Chlamydia trachomatis 
(25.85%), anogenital herpes (24.49%), 
Neisseria gonorrhoea (22.87%), syphilis 
(13.41%), scabies/pediculosis (10.19%), 
HIV (9.51%), Mycoplasma genitalium 
(4.88%), hepatitis B (0.73%), lympho-
granuloma venereum (0.45%) and 
hepatitis C (0.09%). Table 1 summarises 
the main findings across the participant 
sample.
To assess the predictors of STI 
screening, participants were divided 
into two groups: those who had 
never been screened (n=242, 17.9%) 
and those who had had at least one 
previous screening. Those who had 
been screened had a higher frequency 
of alcohol/substance use (χ2=27.2, 
p=0.002), higher use of mobile phone 
applications for casual sex (χ2=15.7, 
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Table 1 Demographic, behavioural and sexually transmitted infection findings in the 
participants
Variable Responses Had been tested for 
STIs/HIV (n=1103)
Never been tested for 
STIs/HIV (n=242)
P value
n % n %
Age range (years) <20 8 0.73 33 13.64 0.0001*
21–25 274 24.84 78 32.23
26–30 540 48.96 53 21.90
31–35 238 21.58 52 21.49
>36 43 3.90 26 10.74
Alcohol/substance use 
before sex
Always 427 38.71 39 16.12 0.0001*
Never 385 34.90 177 73.14
Sometimes 291 26.38 26 10.74
Use of mobile applications 
to find sexual partners
Always 501 45.42 61 25.21 0.0001*
Never 268 24.30 141 58.26
Sometimes 334 30.28 40 16.53
Perceived risk of HIV Yes 404 36.63 41 16.94 0.0001*
No 526 47.69 87 35.95
Don't know 173 15.68 114 47.11
Hepatitis B vaccination Vaccinated 489 44.33 169 69.83 0.02*
Not 
vaccinated
614 55.67 73 30.17
HPV vaccination Vaccinated 43 3.90 0 0.00 0.29
Not 
vaccinated
1060 96.10 242 100.00
Protected sexual 
encounters on the last 10 
occasions (n)
0 88 7.98 71 29.34 0.02*
1–5 138 12.5 42 17.36
6–9 447 40.53 72 29.74
10 430 38.98 57 23.55
Mean 7.40, SD 3.11 Mean 5.20, SD 4.24
Condyloma/genital warts Yes 399 36.17 12 4.96 0.007*
No 704 63.83 230 95.04
Chlamydia Yes 153 13.87 29 11.98 0.04*
No 950 86.13 213 88.02
Gonorrhoea Yes 110 9.97 31 12.81 0.035*
No 993 90.03 211 87.19
Herpes Yes 138 12.51 29 11.98 0.95
No 965 87.49 213 88.02
Mycoplasma genitalium Yes 22 1.99 7 2.89 0.98
No 1081 98.01 235 97.11
Syphilis Yes 116 10.52 7 2.89 0.17
No 987 89.48 235 97.11
HIV Yes 73 6.62 7 2.89 0.43
No 1030 93.38 235 97.11
Scabies/pediculosis Yes 44 3.99 15 6.20 0.7
No 1059 96.01 227 93.80
Lymphogranuloma 
venereum
Yes 5 0.45 0 0.00 0.8
No 1098 99.55 242 100.00
Hepatitis B Yes 8 0.73 0 0.00 0.97
No 1095 99.27 242 100.00
Continued
Library. Protected by copyright.
 o
n
 April 2, 2020 at Nottingham
 Trent Univ The Boots
http://jfprhc.bmj.com/
BM
J Sex Reprod Health: first published as 10.1136/bmjsrh-2019-200415 on 6 February 2020. Downloaded from 
BMJ Sex Reprod Health Month 2020 Vol 0 No 02
Letter
p<0.001), higher perceived HIV 
risk (χ2=17.7, p<0.001) and higher 
frequency of unprotected sex (χ2=20.2, 
p=0.02).
These results suggest that those 
who engage in sexual risk behaviours 
(alcohol/substance use, use of mobile 
phone applications to find sexual 
partners, frequent unprotected inter-
course) and who appraise their risk to 
be high are more likely to have been 
tested for HIV/STIs than those who 
do not. The findings suggest a multi- 
pronged strategy to prevent HIV and 
other STIs in Lebanon where the Joint 
United Nations Programme on HIV 
and AIDS (UNAIDS) treatment target 
to help end the AIDS epidemic (‘90-
90-90’, ie, 90% diagnosed, 90% on 
treatment, 90% virally supressed) is 
far from being achieved. First, there is 
a lack of data in Lebanon, therefore a 
representative national assessment of 
sexual health in Lebanese MSM should 
be conducted. Second, beside condom 
use, other preventive interventions 
targeting substance use in sexualised 
settings (known as ‘chemsex’3) and 
varied sexual networks based on active 
dating applications usage4 5 should be 
developed. HIV pre- exposure prophy-
laxis would be a valuable component of 
the national prevention strategy. Sexual 
health risks specific to MSM need to 
be highlighted to individuals from this 
population who never test for STIs. 
Third, in Lebanon where homosexu-
ality is socially stigmatised, MSM may 
have decreased access to sexual health 
promotion and HIV prevention infor-
mation.2 This can be translated into 
a gap in self- risk assessment amid a 
60% prevalence of unprotected sexual 
intercourse. Fourth, in order for us to 
achieve ‘90-90-90’ in Lebanon, our 
recommendation is to integrate sexual 
and reproductive healthcare services to 
improve access for key populations in 
line with the Regional World Health 
Organization (WHO) strategy. More 
generally, breaking the barriers of stig-
matisation and criminalisation of Leba-
nese MSM can effectively improve our 
ability to target and serve this high- risk 
population with comprehensive preven-
tive services.
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Variable Responses Had been tested for 
STIs/HIV (n=1103)
Never been tested for 
STIs/HIV (n=242)
P value
n % n %
Hepatitis C Yes 1 0.09 0 0.00 0.99
No 1102 99.91 242 100.00
Never had any STI Yes 428 38.80 146 60.33 0.02*
No 675 61.20 96 39.67
*Significant statistical result (p<0.05).
HIV, human immunodeficiency virus; HPV, human papillomavirus; SD, standard deviation; STI, sexually transmitted 
infection.
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